Non drug-related and opioid-specific causes of 3262 deaths in Scotland's methadone-prescription clients, 2009-2015 by Gao, Lu et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non drug-related and opioid-specific causes of 3262 deaths in
Scotland's methadone-prescription clients, 2009-2015
Citation for published version:
Gao, L, Robertson, JR & Bird, SM 2019, 'Non drug-related and opioid-specific causes of 3262 deaths in
Scotland's methadone-prescription clients, 2009-2015' Drug and Alcohol Dependence, vol. 197, pp. 262-
270. DOI: 10.1016/j.drugalcdep.2019.01.019
Digital Object Identifier (DOI):
10.1016/j.drugalcdep.2019.01.019
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Drug and Alcohol Dependence
Publisher Rights Statement:
This is an open access article under the CC BY license
(http://creativecommons.org/licenses/BY/4.0/).
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 08. Jul. 2019
Contents lists available at ScienceDirect
Drug and Alcohol Dependence
journal homepage: www.elsevier.com/locate/drugalcdep
Full length article
Non drug-related and opioid-specific causes of 3262 deaths in Scotland’s
methadone-prescription clients, 2009–2015
Lu Gaoa, J. Roy Robertsonb, Sheila M. Birda,c,⁎
aMRC Biostatistics Unit, University of Cambridge School of Clinical Medicine, Cambridge CB2 0SR, United Kingdom
bUniversity of Edinburgh Usher Institute, Edinburgh EH8 9AG, United Kingdom
cUniversity of Edinburgh Centre for Medical Informatics, Edinburgh EH16 4UX, United Kingdom
A R T I C L E I N F O
Keywords:
Methadone clients
Drugs-related deaths
Methadone-specific deaths
Age-group
Co-present circulatory, respiratory or digestive
disease
Quantity of prescribed methadone
Interaction between quantity and age-group
Age-related predominance of non drug-related
deaths
A B S T R A C T
Background: Opioid drug use is a major cause of premature mortality, with opioid substitution therapy the
leading intervention. As methadone-clients age, non-drug-related deaths (non-DRDs) predominate and DRD-
risks increase differentially, quadrupling at 45+ years for methadone-specific DRDs.
Methods: 36,606 methadone-prescription-clients in Scotland during 2009–2015 were linked to mortality records
to end-2015 by their Community Health Index (CHI). Cohort-entry, also baseline quantity of prescribed me-
thadone, were defined by clients’ first CHI-identified methadone-prescription during 2009–2015. National
Records of Scotland identified non-DRDs from DRDs; and provided ICD10 codes for underlying and co-present
causes of death. Methadone-specific DRD means methadone was implicated in DRD but neither heroin nor
buprenorphine.
Results: During 193,800 person-years of follow-up, 1939 non-DRDs (59%) and 1323 DRDs occurred, of which
546 were methadone-specific. Predominant underlying ICD10 chapters for non-DRDs were: neoplasm (377);
external causes (341); diseases of digestive (303), circulatory (286) or respiratory (212) system. As methadone-
clients aged, the non-DRD proportion of their deaths increased from 54% (717/1318) at 35–44 years to 89%
(372/417) at 55+ years.
After allowing for DRDs’ opioid-specificity, age-group and quintile for last-prescribed methadone, there was a
significant, positive interaction for co-present circulatory disease between top-quintile for prescribed methadone
and 45+ years at death (p = 0.033 after Bonferroni); not for digestive or respiratory co-presence.
Conclusions: Circulatory disease is the co-morbidity most likely implicated in the quadrupling of methadone-
specific DRD-risk at 45+ years; followed by digestive disease. Cultural shift is needed in treatment-services
because degenerative non-DRDs predominate as methadone-clients age. Future linkage-studies should access
hospitalizations and methadone-daily-dose.
1. Introduction
For Scotland, we planned to document ageing methadone-clients’
non drug-related deaths (non-DRDs) and investigate which of three
major co-morbidities (circulatory, digestive, respiratory) might be im-
plicated in clients’ steep rise in methadone-specific DRDs with age.
Scene-setting: In Europe and North America, the majority of DRDs is
opioid-related. Survivors of the heroin-injector epidemics of the late
1970s and early 1980s, now in their 40 s and 50 s, mostly receive opioid
substitution therapy which, in the UK, is methadone predominantly.
North America’s dramatic recent rise in opioid-related DRDs has
been exacerbated by fentanyl; but also by the over-prescription of
opiates for pain management which is an additional reason for opioid-
related DRDs there to be ageing.
There is strong evidence that opioid users’ DRD-risk increases with
age; and that younger females are at much lower DRD-risk than young
males, an advantage which diminishes with age. In the UK, evidence of
these demographic influences is consistent across a) evidence-synth-
eses, b) cohort studies and c) official statistics (Bird et al., 2010; Merrall
et al. (2012); King et al. (2014, 2013); Pierce et al. (2015a, 2015b);
White et al., 2015; Gao et al., 2016; National Records of Scotland
(NRS), 2018).
More recently, Gao et al. (2016) and Pierce et al. (2018) showed
that the risk of methadone-specific DRD (that is: methadone implicated
in DRD but neither heroin nor buprenorphine) rises steeply with age,
quadrupling at 45+ years of age compared with 25–34 years. They
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speculated that circulatory, digestive or respiratory co-morbidities
might be implicated.
Only cohort studies reveal non-DRD mortality and morbidity rates:
Uncounted by official statistics is the predominance of non-DRDs as
opioid users age. People who use drugs have a range of physical co-
morbidities, which may potentiate opioid-related DRD-risks and are
themselves major causes of non-DRDs. Important among them are
diseases of the circulatory, gastrointestinal (including liver) and re-
spiratory systems (Degenhardt et al., 2009; Merrall et al., 2013; Merrall
ELC, 2012; Pierce et al., 2015b).
Smoking is a major risk-factor for both circulatory and respiratory
disease while hepatitis viruses, alcohol misuse and obesity all herald
liver disease. Half of Scotland’s prisoners with a history of injection
drug use are Hepatitis C virus (HCV) carriers, as revealed in prison
studies from 1994 to 2010 (Gore et al., 1999; Taylor et al., 2013).
Diagnosis of HCV, older age (35+ years) and declared misuse of
alcohol were the top three predictors for Scottish Drugs Misuse
Database clients’ risk of death from digestive system disease in
1996–2006 (Merrall ELC, 2012). Cause-specific mortality in 2005–2009
for over 150,000 opiate-dependent clients in England’s National Drug
Treatment Monitoring System revealed two underlying causes which
accounted for at least 10% of client-deaths, namely: circulatory (418
cases) and digestive system disease (423 cases). The same two topped
Scottish clients’ list of hospital-episode-rates by discharge-diagnosis: 25
hospital-episodes per 1000 person-years (digestive), 18 (circulatory),
with 14 per 1000 person-years for respiratory disease (Merrall et al.,
2013; Merrall ELC, 2012).
Opioid-specificity of DRDs, as documented by official statistics:
Scotland’s methadone-related deaths have been a major concern since
2011 when, for the first time, they outnumbered Scotland’s heroin-re-
lated deaths (Ferguson, 2012; Scottish Drug Strategy Delivery
Commission, 2013; Strang et al., 2010). Near equality occurred in 2012,
2013 and again in 2017 (National Records of Scotland, 2018).
Hence, Gao et al. (2016) investigated the opioid-specificity of DRDs
experienced by Scotland’s methadone-prescription-clients in
2009–2013. Their key finding was that the hazard-rate for methadone-
specific DRD increased steeply with age-group, doubling at 35–44 years
and nearly quadrupled at 45+ years (versus 25–34 years), both in
Scotland and England (Gao et al., 2016; Pierce et al., 2018).
But underlying mechanisms are not well understood (Hickman
et al., 2018), with the following potentially implicated: co-morbid cir-
culatory, digestive or respiratory disease; quantity of prescribed me-
thadone; altered half-life of methadone by gender, age-group or liver
disease; and co-prescribing for mental ill-health (Gao et al., 2016;
Pierce et al., 2018).
Capitalizing on co-morbidities determined at forensic autopsy:
Understanding whether ageing methadone-clients’ pre-existing co-
morbid conditions influence the opioid-specificity of their DRDs is now
critical. Since DRDs are subject to forensic autopsy, co-morbid condi-
tions recorded for DRDs have the advantage of histopathological as-
sessment. In addition, a national protocol for toxicology at forensic
autopsy in Scotland underpins the opioid-specificity of Scotland’s DRDs.
In this paper, we revisit Scotland’s methadone-prescription-client
cohort, this time for 2009–2015, first to elucidate the increasingly-aged
clients’ major causes of non-DRDs and secondly to clarify how three
major co-morbidities (circulatory, digestive, respiratory) relate to the
opioid-specificity of DRDs, prescribed methadone and age-group.
Both objectives will be addressed by analysing how major chapters
of the International Classification of Diseases (10th edition, ICD10)
account for underlying and co-present causes of death for Scotland’s
2009–2015 methadone-prescription-client cohort. We estimated that
linkage to mortality records to 31 December 2015 would yield around
3200 deaths, including 1200 DRDs (half of them methadone-specific);
and that several ICD10 chapters, including for circulatory, digestive and
respiratory diseases, would be underlying for 250–350 deaths but co-
present for up to twice as many. The quantity of prescribed-methadone
was available for each prescription.
The present study aims to do the following:
i) highlight major ICD10-chapters for the underlying cause of ageing
methadone-prescription-clients’ death when death is non-DRD;
ii) identify whether the ICD10-chapters for circulatory, digestive and
respiratory disease are differentially co-present at opioid-specific
DRDs (especially at 45+ years of age);
iii) summarize quantity of prescribed methadone for opioid-specific
DRDs and for non-DRDs (especially at 45+ years of age);
iv) derive logistic risk-scores for co-presence of circulatory, digestive or
respiratory disease, which take into account opioid-specificity, age-
group at DRD and quintile for quantity of prescribed methadone;
v) within each risk-score, test for a significant positive interaction
between top quintile of prescribed methadone and 45+ years of
age.
2. Methods
2.1. Definitions: Drug-related Deaths; and ICD10 Coding for all Deaths
We used the UK harmonized definition of DRD (National Records of
Scotland, 2017) and requested information on the opioid-specificity of
Scotland’s DRDs from NRS as follows:
methadone-specific DRDs: methadone was implicated in DRD but
neither heroin/morphine nor buprenorphine implicated;
heroin-specific DRDs: heroin/morphine was implicated in DRD
but neither methadone nor buprenorphine implicated; and
heroin-methadone DRDs: methadone and heroin/morphine both
implicated but buprenorphine was not implicated.
In appraising which drugs are implicated as causal factors in any
DRD and which, although present, probably did not contribute,
Scotland’s pathologists are supported by having a national protocol for
toxicological testing at forensic autopsies.
For each death, in addition to underlying cause of death, NRS also
provided all mentioned ICD10 sub-codes.
2.2. Scotland’s Community Health Index (CHI)
Scotland’s CHI is a register of all patients in NHS Scotland,
Scotland’s publicly funded healthcare system. Patients are identified by
a 10-digit CHI-number, usually the patient’s date of birth (DDMMYY)
followed by four digits: two randomly generated, the third identifying
gender (odd for males), and the fourth a check-digit. See Pavis and
Morris (2015) on the importance of CHI-numbers for Scotland’s trusted
record-linkage.
2.3. Scotland’s Methadone-prescription-client Cohort for 2009–2015:
Data-sources and Linkage
Methadone prescriptions are held within the Scottish National
Prescribing Information System (Alvarez-Madrazo et al., 2016): most
are CHI-identified and all give quantity of methadone prescribed. Nei-
ther daily-dose of prescribed methadone nor the prescription’s duration
is routinely available electronically as neither is needed for reimbursing
pharmacists.
To define Scotland’s methadone-prescription-client cohort for
2009–2015, nearly 3 million methadone prescriptions during 1 July
2009 to 30 June 2015 had to be linked to NRS’s mortality records to 31
December 2015. Because all deaths are CHI-identified, Scotland’s CHI-
number (if available per-prescription) was used for this exact linkage.
The CHI-number was also used to link serial CHI-identified methadone-
prescriptions for the same client.
For CHI-indexed methadone-prescriptions, we obtained data as
follows: client’s gender and age in completed years at 1 July of pre-
scription-year, enabling analysis by age-group at death (coded:< 35
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years, 35–44, 45–54, 55+ years); prescription-date (when missing, the
later re-imbursement date was used); re-imbursement-date; quantity of
prescribed methadone per prescription; daily-dose of prescribed me-
thadone and duration of prescription (if extractable from electronic
messaging using Natural Language Programs at Information Services
Division); full date of death; ICD10 codes for underlying and co-present
causes of death; whether the underlying (ie main) cause of death was
DRD or non-DRD.
As full date of death is potentially identifying, computations were
conducted via the Farr Institute’s safe-haven in Scotland.
2.4. Inclusion/Exclusion Criteria
We defined Scotland’s methadone-prescription-client cohort for
2009–2015 as: clients who had received one or more CHI-identified
methadone prescription (from general practitioner (GP) or other
sources) during 1 July 2009 to 30 June 2015. Client’s date of accrual
was date of the client’s first CHI-identified methadone prescription
during 1 July 2009 to 30 June 2015. That prescription also defined the
client’s baseline quantity of prescribed methadone and age-group at
accrual (< 25 years, 25–34, 35–44, 45+ years).
Initial check on the integrity of date-sequences was made by com-
puting the time interval in days from the date of the client’s baseline
CHI-identified methadone prescription to the earlier of death-date and
31 December 2015. Sixty-three negative survival times were referred
back to Information Services Division for cross-checking, only seven of
which were considered to be incorrectly linked; and have been deleted.
As in Gao et al. (2016), we otherwise added a fixed number of days
(here 60 days) to all survival intervals to ensure positivity.
2.5. Key Variables
The opioid-specificity of DRDs, defined above, was a primary con-
sideration.
Age-group at accrual (< 25 years, 25–34, 35–44, 45+ years) was
defined for consistency with Gao et al. (2016) but age-group at sub-
sequent death was more appropriately defined as:< 35 years, 35–44,
45–54, 55+ years.
Quantity of prescribed methadone (either at baseline or according
to the latest CHI-identified prescription in the year prior to death) was
summarized by mean (sd) and inter-quartile range; or quintiles.
In logistic regression for the odds on co-present circulatory, diges-
tive or respiratory disease, quantity prescribed was analysed by quin-
tiles as in Gao et al. (2016) but abbreviated to bottom, mid, top quin-
tiles and the quantity-age interaction to be tested was defined by: top
quintile for quantity of prescribed-methadone (based on the latest CHI-
identified prescription in the year prior to death) and aged 45+ years
at death.
2.6. Statistical Analysis
We first documented underlying cause of death by ICD10 chapter;
then ICD10 chapters of which there was any-mention in the cause of
death for Scotland’s methadone-prescription cohort in 2009–2015.
Next, we assessed whether the age-related pattern of co-present
mentions of specific ICD10-chapters was different by DRDs’ opioid-
specificity, notably for circulatory, digestive or respiratory disease and
methadone-specific DRDs. We added undetermined intent (Y-codes)
post hoc. Differential patterns at 45+ years of age could potentially
shed light on the co-morbidities that might account for the steeply in-
creased hazard ratios by age for methadone-specific DRD, as previously
documented by Gao et al. (2016) and Pierce et al. (2018).
By age-group, we also compared the mean quantity of prescribed
methadone at baseline (and at latest CHI-identified prescription in the
year prior to death) for those whose subsequent death was methadone-
specific DRD or otherwise.
Finally, we derived logistic regression-scores for the co-presence at
opioid-specific DRDs of circulatory; digestive; respiratory disease (prior
hypotheses); or undetermined intent (Y-code). Besides opioid-specifi-
city, age-group at death and quintile for latest quantity of prescribed
methadone in the deceased’s final-year were fitted; and an interaction
between top quintile for prescribed methadone and age 45+ years at
opioid-specific DRD was tested for. The reported interaction p-value
should be multiplied by 3, as a Bonferroni correction for having had
three prior hypotheses.
For translating from odds [O] on co-present circulatory disease to
estimated probability [P] of co-present circulatory disease, use: P=O/
[1+O].
3. Results
3.1. Scotland’s 2009–2015 Methadone-prescription-client Cohort
During 1 July 2009 to 30 June 2015, Scotland had 2,922,052 me-
thadone prescriptions. As in Gao et al. (2016), the percentage of CHI-
identified methadone prescriptions was 66% (1,932,090/2,922,052)
but the estimated proportion of methadone-prescription-clients with at
least one CHI-identified prescription in 2009–2015 was 80% (36,606/
46,000 to nearest 100).
The majority (57%, 20,757 clients) joined the CHI-identified cohort
of methadone-prescription-clients during July to December 2009, being
mostly prevalent clients, see Table 1. During 193,813 person-years of
follow-up to 31 December 2015, there were 3262 deaths. The cohort
experienced 1939 non-DRDs (59%) and 1323 DRDs: rates of 10.0 non-
DRDs (95% CI: 9.5–10.5) and 6.8 DRDs (95% CI: 6.4–7.2) per 1000 pys
respectively.
The GP-subset (44%) of 10,380 methadone-prescription-clients for
whom baseline daily dose of prescribed methadone was available
electronically had significantly lower rates of non-DRDs (9.0; 95% CI:
8.3–9.8) and DRDs (5.7; 95% CI: 5.1–6.3) per 1000 pys than all other
clients for whom daily dose was not available (non-DRDs 10.5; 9.9–11.0
and DRDs 7.4; 95% CI: 6.9–7.8).
3.2. Underlying Cause of Death by Age-group at Death
Of all 3262 deaths, 1323 (41%) were DRDs, of which 1175 (89%)
were opioid-specific: 546 methadone-specific; 320 heroin-specific; both
heroin and methadone (but not buprenorphine) implicated in 309
DRDs. Buprenorphine was implicated in 27 DRDs. There were 121
DRDs in which none of heroin/morphine, methadone or buprenorphine
was implicated.
Five underlying or main causes of death, each responsible for at
least 10% of 1939 non-DRDs, together accounted for 75% (1457) of
methadone-prescription-clients’ non-DRDs: neoplasms (377, 21%, of
which 113 were malignant neoplasm of unspecified part of bronchus or
lung); external causes of morbidity and mortality (primarily accidents,
other causes of accidental injury, intentional self-harm, assault, events
of undetermined intent, ICD10 code-letters X: 279, 14%; Y: 62, 3%);
diseases of the circulatory (286, 15%), digestive (303, 16%) or re-
spiratory system (212, 11%).
Underlying causes for non-DRDs differed by age-group with neo-
plasms, circulatory, digestive and respiratory system diseases being the
equal-top main causes at 45–54 years (when they accounted for 66% of
non-DRDs) whereas neoplasms alone accounted for 48% of methadone-
clients’ non-DRDs at 55+ years, with circulatory and respiratory causes
being joint-second at 16% each, see Table 2.
Around half (54%, 717) of 1318 deaths aged 35–44 years were non-
DRDs, rising to 65% at 45–54 years (589/907) and 89% (372/417) at
55+ years.
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Table 1
Baseline characteristics for Scotland’s 36,606 CHI-indexed methadone-prescription clients, 2009–2015.
Covariates defined by
1st CHI-identified methadone prescription during
1 July 2009 to 30 June 2015
Clients
N=36,606
Non-DRDs
N= 1,939
DRDs
N= 1,323
PERSON-YEARS (%): mean person-years
(pys) per client
PYS=193,813: 5.3 pys
Cohort-entry period July – Dec 2009 20,757 (57) 1,220 (63) 857 (65) 129,896 (67): 6.3 pys
2010 6,534 (18) 348 (18) 256 (19) 35,409 (18): 5.4 pys
2011 3,034 (8) 153 (8) 111 (8) 13,469 (7): 4.4 pys
2012 1,965 (5) 74 (4) 45 (3) 6,952 (4): 3.5 pys
2013 1,857 (5) 72 (4) 29 (2) 4,694 (2): 2.5 pys
2014 1,704 (5) 56 (3) 23 (2) 2,731 (1): 1.6 pys
January – June 2015 755 (2) 16 (1) 2 (nil) 663 (< 1): 0.9 pys
Prescription source GP-prescription 23,760 (65) 1,426 (74) 847 (64) 131,379 (68): 5.5 pys
Other-source 12,846 (35) 513 (26) 476 (36) 62,434 (32): 4.9 pys
Gender Males 24,369 (67) 1350 (70) 908 (69) 128,492 (66): 5.3 pys
Females 12,237 (33) 589 (30) 415 (31) 65,322 (34): 5.3 pys
Age-group at cohort-entry Under 25 years 2,899 (8) 49 (3) 61 (5) 14,366 (7): 5.0 pys
25 – 34 15,953 (44) 404 (21) 503 (38) 86,812 (45): 5.4 pys
35 – 44 13,498 (37) 804 (41) 565 (43) 72,768 (38): 5.4 pys
45 + years 4,256 (12) 682 (35) 194 (15) 19,868 (10): 4.7 pys
QUINTILE for baseline quantity of prescribed
methadone
Q1: 1–240 mg 7,462 412 223 33,355 (17): 4.5 pys
Q2: 241–616 mg 7,187 406 273 36,654 (19): 4.6 pys
Q3: 617–1120 mg 7,674 373 265 42,553 (22):5.6 pys
Q4: 1121–1960 mg 7,804 413 280 43,656 (23): 5.6 pys
Q5: > =1961mg 7,479 335 282 37,595 (19): 5.0 pys
QUINTILE for available baseline daily-dose of
prescribed methadone
Baseline daily-dose not
available
26,226 (72%) 1,392 (72%) 979 (74%) 132,966 pys (69%): 5.1 pys
Q1: 1 - 30 mg 2,350 173 72 13,008 (7): 5.5 pys
Q2: 31 - 50 mg 2,206 104 67 12,965 (7): 5.9 pys
Q3: 51 - 70 mg 2,182 113 71 13,006 (7): 6.0 pys
Q4: 71 - 90mg 1,844 76 66 11,066 (6): 6.0 pys
Q5: 91 – 280 mg 1,798 81 68 10,802 (6): 6.0 pys
Boldface: for headings.
Table 2
Underlying (or main) ICD10 chapter for all 1939 non-DRDs; by age-group at death.
ICD10 codes ICD10 chapter, see http://apps.who.int/
classifications/icd10/browse/2010/en
Age-at-death frequency of ICD10 chapter for underlying causes of methadone-prescription-clients’ non-
DRDs
Frequency
(%) in 1939
non-DRDs
Frequency
(%) in 261 clients
aged
< 35 years
at death
Frequency
(%) in 717 clients
aged
35-44 years
at death
Frequency
(%) in 589 clients
aged
45-54 years
at death
Frequency
(%) in 372 clients
aged
55+ years
at death
A Certain infectious and parasitic diseases 26 (1.3) 5 (1.9) 10 (1.4) 9 (1.5) 2 (0.5)
B 83 (4.3) 1 (0.4) 34 (4.7) 37 (6.3) 11 (3.0)
C Neoplasms 377 (19.4) 14 (5.4) 78 (10.9) 108 (18.3) 177 (47.6)
E Endocrine, nutritional and metabolic diseases 35 (1.8) 8 (3.1) 16 (2.2) 9 (1.5) 2 (0.5)
F Mental and behavioural disorders 120 (6.2) 30 (11.5) 48 (6.7) 34 (5.8) 8 (2.2)
G Diseases of nervous system 26 (1.3) 2 (0.8) 8 (1.1) 12 (2.0) 4 (1.1)
I Diseases of circulatory system 286 (14.8) 20 (7.7) 114 (15.9) 93 (15.8) 59 (15.9)
J Diseases of respiratory system 212 (10.9) 7 (2.7) 63 (8.8) 85 (14.4) 57 (15.3)
K Diseases of the digestive system 303 (15.6) 34 (13.0) 137 (19.1) 104 (17.7) 28 (7.5)
R Symptoms, signs and abnormal clinical and laboratory
findings, not elsewhere classified
37 (1.9) 6 (2.3) 16 (2.2) 12 (2.0) 3 (0.8)
X External causes of morbidity and mortality 279 (14.4) 91 (34.9) 131 (18.3) 47 (8.0) 10 (2.7)
Y 62 (3.2) 20 (7.7) 28 (3.9) 14 (2.4) Nil
Selected sub-codes: respiratory; digestive system; external causes
J09-18 Influenza and pneumonia 53 (2.7) 4 (1.5) 22 (3.1) 19 (3.2) 8 (2.2)
J40-47 Chronic lower respiratory disease 134 (6.9) 3 (1.2) 35 (4.9) 55 (9.3) 41 (11.0)
K70-77 Liver disease 265 (13.7) 29 (11.1) 123 (17.2) 94 (16.0) 19 (5.1)
K70 Alcoholic liver disease 213 (11.0) 25 (9.6) 102 (14.2) 75 (12.7) 11 (3.0)
K74 Fibrosis and cirrhosis 31 (1.6) 3 (1.2) 12 (1.7) 12 (2.0) 4 (1.1)
X65-84
Y15-34
Non-DRD suicide 191 (9.9) 63 (24.1) 95 (13.2) 32 (5.4) 1 (0.3)
X86-Y09 Homicide 56 (2.9) 23 (8.8) 21 (2.9) 8 (1.4) 4 (1.1)
Boldface: for underlying ICD10 chapters which accounted for more than 5% of 1939 non-DRDs; and, for them, to highlight significantly differential frequency by
age-group.
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3.3. Co-present ICD10 Codes by Age-group at Death and Opioid-specificity
of DRD
For co-present circulatory, digestive or respiratory system disease
and for ICD10 code-letters X and Y (undetermined intent), Table 3 gives
the age-group at death for non-DRDs versus for opioid-specific DRDs;
and for all 3262 deaths.
Methadone-prescription-clients whose death was non-DRD were
notably older, with 49% of such deaths having occurred at 45+ years of
age. By contrast, those aged 45+ years at death accounted for only
187/546 (34%) of methadone-specific DRDs, 58/320 heroin-specific
DRDs (18%) and 78/309 DRDs in which both heroin and methadone
were implicated (25%).
Circulatory disease featured in 11% of all methadone-specific DRDs
but for only 5.7% of DRDs in which heroin was implicated (36/629).
Circulatory disease was mentioned for 34/187 (18%) methadone-spe-
cific DRDs at 45+ years of age but for only 12/136 (9%) heroin-im-
plicated deaths aged 45+ years (p= 0.0232, Fisher’s exact test).
Respiratory disease was mentioned in 14% of methadone-specific
DRDs and for 7.6% of DRDs in which heroin was implicated (48/629).
Respiratory disease was mentioned for 41/187 (22%) methadone-spe-
cific DRDs at 45+ years of age and similarly for 27/136 (20%) heroin-
implicated deaths aged 45+ years.
Digestive system disease was mentioned for 8% of all methadone-
specific DRDs but for only 1.4% of DRDs in which heroin was im-
plicated (9/629; p < 0.00001 for all ages). Table 3 also shows that
digestive disease was co-present for 19/187 (10%) methadone-specific
DRDs at 45+ years of age versus for 5/136 heroin-implicated DRDs
aged 45+ years (4%: p= 0.0317, Fisher’s exact test).
Finally, undetermined intent was mentioned for 20% of 546 me-
thadone-specific DRDs, which is twice as often as for DRDs in which
heroin was implicated (9%, 58/629, p < 0.00001). For those aged
45+ at death, intent was undetermined for 28/187 methadone-specific
DRDs (15%) and for 11/136 heroin-implicated DRDs (8%: p=0.0828,
Fisher’s exact test).
3.4. Quantity of Methadone prescribed by Age-group at Death and Opioid-
specificity of DRD
By age-group at death for opioid-specific DRDs versus non-DRDs,
Table 4 summarizes the quantity of methadone prescribed at baseline;
and at the latest CHI’d prescription in the year prior to death. As ex-
plained in Methods, the period prescribed-for (whether 1 week or less;
2, 4 or 8 weeks; or longer) was not, in general, available electronically.
Irrespective of age-group, the mean baseline quantity of prescribed
methadone was higher at 1588mg (95% CI: 1461–1715) for metha-
done-specific DRDs than for non-DRDs at 1142mg (95% CI:
1092–1192); and for heroin-specific DRDs at 919mg (95% CI:
Table 3
Age-group at death for non-DRDs versus for opioid-specific DRDs – for selected co-present ICD10 chapters, including Y for undetermined intent. Boldface for ICD10
chapters and Totals.
Age-group at death (%) Sub-grouping of all deaths Total of
3262 deaths
1939
Non-DRDs
546 Methadone-specific DRDs 320
Heroin-specific DRDs
309
Methadone+ heroin DRDs
< 35 years 261 (13.5) 123 (22.5) 107 (33.4) 96 (31.1) 620 (19.0)
35-44 years 717 (37.0) 236 (43.2) 155 (48.4) 135 (43.7) 1318 (40.4)
45-54 years 589 (30.1) 165 (30.2) 53 (16.6) 70 (22.7) 907 (27.8)
55+ years 372 (19.2) 22 (4.0) 5 (1.6) 8 (2.6) 417 (12.8)
Totals 1939 546 320 309 3262
Co-present ICD10-code frequencies
[relative frequency as % of the above age- and sub-group specific deaths]
ICD10 code-I: diseases of the circulatory system
< 35 years 41 [16%] 7 [6%] 4 [4%] 3 [3%] 59 [10%]
35-44 years 190 [27%] 20 [9%] 11 [7%] 6 [4%] 230 [18%]
45-54 years 157 [27%] 25 [15%] 2 [4%] 8 [11%] 197 [22%]
55+ years 115 [31%] 9 [41%] 1 1 [13%] 128 [31%]
Totals 503 [26%] 61 [11%] 18 [6%] 18 [6%] 614 [19%]
ICD10 code-J: diseases of the respiratory system
< 35 years 27 [10%] 7 [6%] 1 [1%] 6 [6%] 42 [7%]
35-44 years 143 [20%] 26 [11%] 3 [2%] 11 [8%] 189 [14%]
45-54 years 185 [31%] 31 [19%] 9 [17%] 14 [20%] 241 [27%]
55+ years 131 [35%] 10 [46%] 1 [20%] 3 [38%] 146 [35%]
Totals 486 [25%] 74 [14%] 14 [4%] 34 [11%] 618 [19%]
ICD10 code-K: diseases of the digestive system
< 35 years 47 [18%] 6 [5%] 1 [1%] 1 [1%] 56 [9%]
35-44 years 211 [29%] 21 [9%] 1 [1%] 1 [1%] 235 [18%]
45-54 years 188 [32%] 15 [9%] 1 [2%] 4 [6%] 208 [23%]
55+ years 59 [16%] 4 [18%] 0 0 63 [15%]
Totals 505 [26%] 46 [8%] 3 [1%] 6 [2%] 562 [17%]
ICD10 code-X: within external causes of morbidity and mortality
< 35 years 122 [47%] 89 [72%] 95 [89%] 84 [88%] 410 [66%]
35-44 years 186 [26%] 183 [78%] 142 [92%] 122 [90%] 672 [51%]
45-54 years 92 [16%] 139 [84%] 47 [89%] 62 [89%] 354 [39%]
55+ years 22 [6%] 15 [68%] 5 8 [all] 56 [13%]
Totals 422 [22%] 426 [78%] 289 [90%] 276 [89%] 1492 [46%]
ICD10 code-Y (includes undetermined intent): within external causes
< 35 years 21 [8%] 30 [24%] 11 [10%] 11 [12%] 76 [12%]
35-44 years 39 [5%] 49 [21%] 12 [8%] 13 [10%] 117 [9%]
45-54 years 24 [4%] 21 [13%] 4 [8%] 7 [10%] 58 [6%]
55+ years 10 [16%] 7 [32%] 0 0 18 [4%]
Totals 94 [5%] 107 [20%] 27 [8%] 31 [10%] 269 [8%]
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822–1016), all confidence intervals non-overlapping.
The corresponding mean quantities of prescribed methadone in the
year prior to death were lower by 15%, 18% and 34% respectively, at
1346mg (95% CI: 1229–1463) for 498/546 (91%) methadone-specific
DRDs versus 937mg (95% CI: 891–983) for 1624/1933 (84%) non-
DRDs; and 610mg for 176/320 (55%) heroin-specific DRDs (95% CI:
501–719), all confidence intervals again non-overlapping - with each
other and their baseline counterpart.
The proportion of deceased methadone-prescription-clients for
whom we identified a CHI-indexed methadone prescription in the year
prior to death was highest for methadone-specific DRDs (91%, 95% CI:
89%–94%), high also for non-DRDs (84%, 95% CI: 82%–85%); but just
over half for heroin-specific DRDs (55%, 95% CI: 49%–60%).
For methadone-specific DRDs only, the baseline mean quantity
prescribed increased with age-group at death from 1231mg if under 35
years of age (95% CI: 1022 to 1442) through 1686mg for those aged
35–44 years (95% CI for difference in means: 161 to 747mg) to
1700mg in the oldest age-group at death (95% CI for difference be-
tween oldest and youngest: 160 to 776mg). For methadone-specific
DRDs in the year prior to death, mean quantity prescribed did not differ
significantly between the youngest and the oldest age-group (95% CI:
-113 to 431mg).
3.5. Logistic Regression Scores for Co-presence of Circulatory, Digestive or
Respiratory Disease
For Scotland’s methadone-prescription-clients in 2009–2015 with a
CHI-identified methadone-prescription in the year prior to death, the
logistic regressions in Table 5 show that circulatory disease was more
likely to be co-present for methadone-specific DRDs than for heroin-
implicated DRDs; and that the odds increased dramatically with age to
be 12 times higher at 55+ years (95% CI: 4–33) than if aged under 35
years at opioid-specific DRD.
The odds on co-present respiratory disease also increased sharply
with age, being 16 times higher at 55+ years (95% CI: 6–42) than if
aged under 35 years at opioid-specific DRD - but opioid-specificity was
not itself strongly influential.
The odds on co-present digestive disease were markedly lower for
heroin-implicated DRDs than for methadone-specific DRDs; and higher
if aged 55+ years at opioid-specific DRD.
Quintile for prescribed methadone was not strongly influential on
the co-presence of any of the three co-morbidities of primary interest
but the top quintile was (just) associated with increased odds on un-
determined intent. Undetermined intent was significantly less likely in
with heroin-implicated DRDs than for methadone-specific DRDs. The
odds on undetermined intent was highest for those aged under 35 years.
3.6. Adding Interaction between Top Quintile for prescribed Methadone and
Older Age at Opioid-specific DRD
The fitted interaction term assessed whether, for those aged 45+
years at the time of opioid-specific DRD, having latterly received the
top quintile of prescribed methadone had was positively associated
with co-presence of circulatory, digestive or respiratory disease.
Only one such interaction term, for co-presence of circulatory dis-
ease, was statistically significant (p= 0.011 before; 0.033 after
Table 4
Quantity of methadone prescribed at baseline and latest CHI-identified quantity in the year prior to death (latest prescriptions: N denotes the number analysed).
Age-group at death
(age-group’s
% frequency within each
sub-group of deaths)
Sub-grouping of all deaths Total of
3262 deaths
1939
Non-DRDs
546 Methadone-specific
DRDs
320
Heroin-specific DRDs
309
Methadone +
heroin DRDs
< 35 years 261 (13.5%) 123 (22.5%) 107 (33.4%) 96 (31.1%) 620 (19.0%)
Quantity of
methadone prescribed:
Mean (sd);
25th, median, 75th
percentile
Baseline quantity:
994 (972);
280, 700, 1400
Baseline quantity:
1232 (1189);
350, 950, 1820
Baseline quantity:
874 (842);
240, 700,1161
Baseline quantity:
1203 (964);
420, 980, 1743
Baseline quantity:
1033 (969);
300, 735, 1400
Latest in year prior to
death, N=228:
1071 (1045);
355, 811, 1400
Latest in year prior to
death, N=108:
1121 (971);
412, 790, 1680
Latest in year prior to
death, N=64:
675 (684);
145, 420, 990
Latest in year prior to
death, N=82:
1078 (957);
275, 760, 1680
Latest in year prior to
death, N=507:
1009 (1019);
300, 770, 1400
35-44 years 717 (37.0%) 236 (43.2%) 155 (48.4%) 135 (43.7%) 1318 (40.4%)
Quantity of
methadone prescribed:
Mean (sd);
25th, median, 75th
percentile
Baseline quantity:
1216 (1133);
360, 980, 1680
Baseline quantity:
1686 (1596);
480,1260, 2240
Baseline quantity:
934 (866);
260, 665, 1400
Baseline quantity:
1358 (1137);
420, 980, 2160
Baseline quantity:
1271 (1212);
360, 980, 1890
Latest in year prior to
death, N=614:
959 (894);
280, 708, 1330
Latest in year prior to
death, N=219:
1508 (1467);
490,1260, 1960
Latest in year prior to
death, N=85:
585 (824);
112, 280, 770
Latest in year prior to
death, N=119:
1011 (905);
270, 770, 1400
Latest in year prior to
death, N=1094:
1039 (1057);
280, 770, 1400
45+ years 961 (49.6%) 187 (34.2%) 58 (18.1%) 78 (25.2%) 1324 (40.7%)
Quantity of
methadone prescribed:
Mean (sd);
25th, median, 75th
percentile
Baseline quantity:
1128 (1147);
245, 735, 1680
Baseline quantity:
1700 (1569);
595,1400, 2240
Baseline quantity:
958 (999);
280, 630, 1400
Baseline quantity:
1147 (1027);
490, 840, 1680
Baseline quantity:
1208 (1215);
280, 840, 1810
Latest in year prior to
death, N=782:
889 (942);
210, 560, 1260
Latest in year prior to
death, N=171:
1280 (1340);
500, 930, 1785
Latest in year prior to
death, N=27:
530 (536);
120, 330, 780
Latest in year prior to
death, N=66:
1154 (871);
420, 980, 1690
Latest in year prior to
death, N=1075:
964 (1012);
264, 644, 1400
Totals 1939 546 320 309 3262
All-ages quantity of
methadone prescribed:
Mean (sd);
25th, median, 75th
percentile
Baseline quantity:
1142 (1121);
280, 840, 1680
Baseline quantity:
1588 (1514);
450,1260, 2205
Baseline quantity:
919 (882);
263, 669, 1380
Baseline quantity:
1256 (1059);
420, 975, 1820
Baseline quantity:
1200 (1177);
308, 840, 1680
Latest in year prior to
death, N=1624:
937 (941);
280, 660, 1330
Latest in year prior to
death, N=498:
1346 (1336);
490, 980, 1820
Latest in year prior to
death, N=176:
610 (735);
120, 330, 870
Latest in year prior to
death, N=267:
1067 (912);
299, 840, 1624
Latest in year prior to
death, N=2676:
1004(1023);
280, 700, 1400
Boldface: for major headings and totals.
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Bonferroni correction). From Table 5, the estimated odds on co-present
circulatory disease at methadone-specific DRD of a 55+ year old me-
thadone-prescription-client who had received top quintile of prescribed
methadone would be:
Odds without interaction: 0.05 * 1 * 11.59 * 1.22=0.71 and so
estimated probability for co-present circulatory disease of 42%
Odds with interaction: 0.06 * 1 * 8.50 * 0.51 * 4.90=1.27 and so
estimated probability for co-present circulatory disease of 56%.
For a client aged 45–54 years:
Odds without interaction: 0.05 * 1 * 3.39 * 1.22= 0.21 and so es-
timated probability for co-present circulatory disease of 17%
Odds with interaction: 0.06 * 1 * 2.44 * 0.51 * 4.90=0.37 and so
estimated probability for co-present circulatory disease of 27%.
See APPENDIX1 for corroborating logistic regressions for all 1175
opioid-specific DRDs using quintile for quantity of methadone pre-
scribed in latest CHI-identified prescription (irrespective of whether
latest was in the year prior to death).
4. Discussion
4.1. Main Findings
As methadone-clients aged, the non-DRD proportion of their deaths
in 2009–2015 increased from 54% (se 1.4%) at 35–44 years through
65% (se 2.0%) at 45–54 years (when neoplasms, circulatory, digestive
and respiratory disease were equal-top) to 89% (se 1.5%) at 55+ years
(when neoplasms alone accounted for 48% of non-DRDs).
Without additional harm reduction, the underlying causes of death
at ages 45–54 years in 2009–2015 are indicative of those likely in
2019–2025 for methadone-clients currently aged 35–44 years.
Second, circulatory and digestive disease were more likely to be co-
present for methadone-specific DRDs than for heroin-implicated DRDs.
Following Gao et al. (2016), we not only allowed for age-relatedness
but also a possible interaction between older age-group at death and top
quintile for the latest CHI-identified prescribed quantity of methadone.
Of our three co-morbidities, significant interaction was demonstrated
for circulatory disease only (after Bonferroni correction: p=0.033).
Age-trends were steep, and broadly similar, for co-present circula-
tory and respiratory disease but less prominent for digestive disease
until clients reached 55+ years. Differential co-presence at methadone-
specific DRDs versus heroin-implicated DRDs was strongest for diges-
tive system disease.
4.2. Additional Observations
Based on prior UK studies by Merrall et al. (2012) and Pierce et al.
(2015b), we had anticipated reasonable power to focus on differential
co-presence of circulatory, digestive and respiratory disease among the
opioid-specific DRDs experienced by Scotland’s 36,606 CHI-identified
methadone-clients in 2009–2015. Data-led, we observed that un-
determined intent was also significantly more likely for methadone-
specific DRDs than for heroin-implicated DRDs and was associated with
the top quintile for prescribed methadone.
The drop-off in CHI-identified prescriptions by the year prior to
Table 5
Logistic regression odds-ratios for co-presence of ICD10-code for circulatory; respiratory; digestive disease at 941 eligible opioid-related DRDs; and for co-presence of
Y-code (undetermined intent). Interaction tested: aged 45+ years at opioid-DRD and quantity of methadone from deceased’s latest CHI-identified prescription in the
year prior to opioid-DRD in top quintile.
Covariate Odds Ratio coefficients (95% confidence interval)**
Circulatory
83 co-present
(without/with interaction)
Respiratory
109
co-present
Digestive
52
co-present
Y-code
135
co-present
Risk-constant relates to baseline individual (methadone-specific DRD, aged < 35 years at death, middle three quintiles of latest methadone prescription in the year prior to death)
Risk-constant 0.05
(0.02 to 0.10)
0.06
(0.03 to 0.12)
0.06
(0.03 to 0.11)
0.05
(0.02 to 0.12)
0.29
(0.19 to 0.43)
Opioid specificity of 941 opioid-related DRDs (baseline: 498 methadone-specific DRDs)
176 Heroin-specific DRDs 0.53
(0.37 to 0.76)
0.50
(0.24 to 1.06)
0.66
(0.32 to 1.33)
0.13
(0.03 to 0.54)
0.50
(0.28 to 0.88)
267 Heroin and methadone-DRD 0.44
(0.24 to 0.82)
0.43
(0.23 to 0.81)
1.01
(0.63 to 1.62)
0.16
(0.06 to 0.44)
0.39
(0.24 to 0.64)
Age-group at opioid-related DRD (baseline: under 35 years of age at death)
35-44 years 1.86
(0.90 to 3.84)
1.92
(0.93 to 3.96)
1.90
(0.97 to 3.69)
1.73
(0.16 to 19.3)
0.84
(0.54 to 1.29)
45-54 years 3.39
(1.61 to 7.13)
2.44
(1.11 to 5.33)
4.76
(2.44 to 9.27)
2.14
(0.87 to 5.27)
0.54
(0.32 to 0.91)
55+ years 11.59
(4.10 to 32.7)
8.50
(2.89 to 25.0)
15.80
(5.93 to 42.1)
4.62
(1.22 to 17.5)
0.52
(0.15 to 1.87)
Quintile for quantity of methadone prescribed based on latest CHI-indexed prescription in the year prior to opioid-related DRD (baseline: 557 in middle three quintiles, 245 to
1889mg)
Bottom: < 245mg
(n= 196)
1.55
(0.86 to 2.80)
1.51
(0.84 to 2.71)
0.79
(0.43 to 1.44)
1.30
(0.58 to 2.90)
0.64
(0.36 to 1.14)
Top: > 1890mg
(n= 188)
1.22
(0.68 to 2.20)
0.51
(0.19 to 1.36)
1.14
(0.68 to 1.90)
1.28
(0.66 to 2.50)
1.58
(1.03 to 1.46)
Interaction: top quintile for quantity of methadone prescribed and aged 45+ years at opioid-related DRD
Top quintile * 45+ years at opioid-DRD 4.90
(1.45 to 16.5)
p-value for INTERACTION P ˜ 0.011 P ˜ 0.30 P ˜ 0.36 P ˜ 0.31
Regression
chi-square (df) with/without INTERACTION
46.35 (8 df)
39.20 (7 df)
56.62 (8 df)
55.56 (7 df)
39.05 (8 df)
38.19 (7 df)
35.45 (8df)
(7df)
Boldface: for covariate headings. **Please see APPENDIX1 for the corresponding Odds Ratios for 1175 opioid-related deaths in which quintile relates to the quantity
of methadone prescribed according to the deceased’s latest CHI-identified methadone-prescription.
1 Supplementary material can be found by accessing the online version of this
paper at http://dx.doi.org10.1016/j.drugalcdep.2019.01.019.
L. Gao, et al. Drug and Alcohol Dependence 197 (2019) 262–270
268
death was greatest for heroin-specific DRDs (down from 320 to 176,
55% of baseline count), and least for methadone-specific DRDs (down
from 546 to 498). Even at baseline, those who subsequently experi-
enced heroin-specific DRD received a significantly lower mean quantity
of methadone (919mg, se 49mg); and lower still in the year prior to
death, when their latest quantity of prescribed methadone had reduced
to a mean of 610mg (se 55mg).
4.3. Strengths and Limitations
Notwithstanding the power of Scotland’s CHI-identified methadone-
prescription-client cohort for investigating co-present circulatory, di-
gestive and respiratory system disease at 1175 opioid-specific DRDs, a
major limitation was that not all methadone-prescriptions are CHI-
identified. Hence, a client’s last CHI-identified methadone-prescription
does not assuredly represent the client’s last methadone-prescription.
Indeed, only 941/1175 (80%) of clients who experienced opioid-spe-
cific DRD had a CHI-identified methadone prescription in the year prior
to death, the proportion was lowest at 55% (176/320) for heroin-spe-
cific deaths. As a precaution, our logistic regressions were repeated
using quintiles of prescribed methadone at latest CHI-identified pre-
scription (whether or not in the year prior to death), see APPENDIX1
for mostly minor differences.
Secondly, clients’ daily-dose of prescribed methadone was not rou-
tinely available in electronic format. Unfortunately, most international
cohorts and also UK coroners’ records lack information on daily-dose of
prescribed methadone (Caul, 2018; Degenhardt et al., 2009; Sordo
et al., 2017; Xia et al., 2015). We must do better.
We did not request linkage to prescriptions for benzodiazepines,
medications for chronic pain or for mental ill-health, primarily because
methadone-clients’ non-prescribed access to such medications cannot
be accounted for.
Co-presence of circulatory, digestive and respiratory system disease
at opioid-specific DRD was ascertained at forensic post-mortem. As
such, the analysed co-presences were pathological surrogates for me-
thadone-clients’ circulatory, digestive and respiratory system co-mor-
bidities in life, which might otherwise be captured (or not) by their
ICD10 discharge-codes from hospitalizations, see Merrall et al. (2013)
and Merrall (2012). We suggest that the post-mortem evidence pre-
sented here constitutes a strong argument for future linkages, in Scot-
land and internationally, to include clients’ ICD10-coded hospitaliza-
tions to learn about diagnosed morbidities. Notice that comorbidities
for non-DRDs would generally have been determined by medical his-
tory without post-mortem evidence.
4.4. Other Evidence and Implications
An international meta-analysis by Sordo et al. (2017) of 19 cohort
studies compared overall mortality and overdose fatalities during and
after opioid substitution for around 130,000 people treated with me-
thadone and 16,000 who received buprenorphine: substantially lower
rates were reported for buprenorphine. However, due to potential
confounding between choice of opioid substitution and clients’ risk-
characteristics, the authors were cautious in drawing inferences about
which opioid substitution to prefer. In a primary care cohort, Hickman
et al. (2018) tried to adjust for confounding between choice of opioid
substitution (methadone versus buprenorphine) and age-group or the
client’s number of co-morbidities but were handicapped in so doing
because DRDs numbered only 87. Interactions with co-morbidity or
age-group were intriguing but tentative: buprenorphine was increas-
ingly favoured when co-morbidities were present; methadone was
preferred under 30 years of age but buprenorphine for new clients aged
50+ years. Hickman et al. (2018) commended switching the patient’s
opioid substitution therapy to account for older age or co-morbidities.
Their recommendation has support in our analysis. However, we do not
under-estimate the difficulties for patients and clinicians: switching is
not risk-free.
Systematic review of opioid drugs in patients with liver disease by
Soleimanpour et al. (2016) noted that, in patients with reduced hepatic
function (Hutchinson et al., 2005a, 2005b; Mcdonald et al., 2008),
clearance of opioids decreases in liver failure and their bioavailability,
including half-life, increases. The World Health Organization’s listing
(World Health Organization, 2014) of people at higher risk of opioid
overdose includes opioid users who have medical conditions such as
HIV, liver or lung disease or suffer from depression; but fails to mention
circulatory disease. Our results call for a re-think on circulatory disease.
Elsewhere we have recommended that older methadone clients
(35+ years) should be offered periodic electrocardiograms if receiving
a higher daily dose of methadone, for example in excess of 90mg, see
Pierce et al. (2018); and also that all methadone-clients should be
prescribed take-home naloxone or naloxone-on-release (Bird et al.,
2017, 2015; Parmar et al., 2016).
4.5. Concluding Remarks
Our results do not undermine the strong evidence-base that, while
clients receive opioid substitution therapy, their risk of dying is sub-
stantially reduced (Kimber et al., 2010; Sordo et al., 2017; Hickman
et al., 2018; Independent Expert Working Group on Drug Misuse and
Dependence, 2017). But our findings do have actionable implications
for clinical practice, namely: the major co-morbidities of ageing me-
thadone-clients need to be mitigated; or better managed.
In particular, clients with circulatory or digestive system disease
(whether HCV or alcohol related) may need their methadone dose to be
reviewed if there is QTc prolongation or if there is prolongation of
methadone’s half-life by liver compromise. Treatment of clients’ HCV-
related liver disease by directly-acting antivirals and smoking cessation
treatment can mitigate leading cancers as well as circulatory, digestive
and respiratory co-morbidities.
In addition, harm reduction – such as electrocardiogram-checks, see
Anchersen et al. (2009); medication-reviews, such as to reduce co-
prescription of benzodiazepines with methadone (Hickman et al., 2018;
Pierce et al., 2015b); and moderated alcohol intake - should be prior-
itized not only to reduce clients’ risk of major causes of non-DRDs but to
help identify older clients whose methadone-dose may need to be re-
duced to below 100mg/day or for whom a switch to buprenorphine
may be considered.
Besides the increased risk of methadone-specific DRD which me-
thadone at too-high a dose may represent for older clients with circu-
latory or digestive disease, our finding of substantially lower quantity of
prescribed methadone in clients who subsequently experienced heroin-
specific DRD reminds readers that sub-therapeutic doses of methadone
risk recourse to heroin.
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